Relay Therapeutics Accounts Payable

Relay Therapeutics (RLAY) currently reports a accounts payable of $11M as of June 2026. That compares with $5.2M in the prior-year period — up 121.4% year over year. Use the charts on this page to explore Relay Therapeutics's accounts payable history and peer comparisons.

Relay Therapeutics's accounts payable increased from $5.2M to $11M — a 121.4% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Relay Therapeutics reported $11M in accounts payable as of June 2026. That compares with $5.2M in the prior-year period — up 121.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $11M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Relay Therapeutics, and consider following RLAY for alerts when major investors trade the stock.

Relay Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $11M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RLAY with unrelated industries.